A PHASE IB-II STUDY OF HIGH-DOSE POST-TRANSPLANT CYCLOPHOSPHAMIDE BORTEZOMIB AND ABATACEPT FOR THE PREVENTION OF GRAFT-VERSUS-HOST DISEASE (GVHD) FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
